Accenture, Merck team with Amazon on cloud-based platform for early stage drug development

StayNTouch PMS
The Merck/Accenture platform will create an open, industry-standard application for core research functions. (StayNTouch)

Accenture and Merck are partnering with Amazon Web Services to create a cloud-based research platform that will help life science companies working on early stages of drug development.

The Merck/Accenture platform will create an open, industry-standard application for core research functions, the companies said. The platform will support application providers, content providers and tech innovators in the life sciences sector.

When launched, it will be able to aggregate, access and analyze research data from multiple applications that will be available through a single set of interfaces in order to boost collaboration across R&D activities.

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

“Pharmaceutical and biotech R&D is evolving rapidly, with advances in biological sciences generating an increase in the volume and diversity of research data,” Brad Michel, Accenture’s managing director of Scientific Informatics Services, said in a statement. “Understanding the industry’s need to drive faster, more efficient and more innovative scientific research, we are pleased to collaborate with Merck, and AWS to launch the platform and associated ecosystem to help our clients accelerate the discovery of new, targeted treatments for patients.”

Accenture and Merck are looking to leverage industry-standard application programming interfaces. Accenture also said it is putting together a precompetitive collaboration to enhance the platform’s capabilities.

Suggested Articles

Galapagos is selling off its contract research organization Fidelta for $37 million to Polish life science company Selvita.

Decentralized study company Medable has raised a large $91 million funding round as it continues to ramp up the deals in 2020.

Biotech IPOs are up over 40% year-to-date, but today’s markets have rewritten the rules for going public. Find out the new best practices for IPOs.